Emission-arkiv - Egetis Therapeutics

23 October, 2019 Interim report January-September 2019 News English Regulatory MAR Report Interim Q3 IR Optional

21 October, 2019 Nomination Committee appointed for the 2020 Annual General Meeting in PledPharma News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional

16 October, 2019 PledPharma approved for listing on Nasdaq Stockholm News Corporate Action Other English Regulatory MAR IR Optional

9 October, 2019 PledPharma and Solasia enter a second license agreement for the development and commercialisation of PledOx® in Asia, targeting neuropathy caused by taxanes and any other chemotherapy News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-pledox

21 August, 2019 Half-Year report January-June 2019 News English Regulatory MAR Report Interim Q2 IR Optional

21 May, 2019 PledPharma completes a Directed New Share Issue of 4,866,665 shares, raising proceeds of SEK 91 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional

21 May, 2019 PledPharma announces intention of a Directed New Share Issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional

7 May, 2019 Report from the Annual General Meeting of PledPharma News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional

6 May, 2019 Interim report January-March 2019 News English Regulatory MAR Report Interim Q1 IR Optional

8 April, 2019 NOTICE OF ANNUAL GENERAL MEETING OF PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional

8 April, 2019 PledPharma’s 2018 annual report published News English Regulatory Listing Regulation Report Annual IR Optional

18 March, 2019 PledPharma’s drug candidate Aladote® granted Orphan Drug Designation News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-aladote

21 February, 2019 Year-end Report January-December 2018 News English Regulatory MAR Report Interim Yearend IR Optional mfn-cus-aladote mfn-cus-pledox

31 January, 2019 Aladote®’s data has been selected for presentation at The International Liver Congress News English Regulatory IR Optional

17 January, 2019 PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium News English Regulatory IR Optional

10 January, 2019 First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma News English Regulatory IR Optional

24 December, 2018 PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote News English Regulatory IR Optional

13 December, 2018 PledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conference News English Regulatory IR Optional

5 December, 2018 PledPharma prepares for listing on the Nasdaq Stockholm main market during 2019 News English Regulatory IR Optional

8 November, 2018 The first patient included in PledPharma’s global Phase III program for PledOx® News English Regulatory IR Optional

26 October, 2018 Nomination Committee appointed for the 2019 Annual General Meeting in PledPharma News English Regulatory IR Optional

23 October, 2018 Interim Report January-September 2018 News English Regulatory MAR Report Interim Q3 IR Optional

28 September, 2018 Study drug for the PledOx® global phase III program delivered News English Regulatory IR Optional

24 September, 2018 Pledpharma announces positive results from the Aladote® proof of principle study News English Regulatory IR Optional

22 August, 2018 Half-Year Report January-June 2018 News English Regulatory MAR Report Interim Q2 IR Optional

Press releases

2019

2018

Calendar and upcoming reports

Contact us

Press releases

2019

2018

Calendar and upcoming reports

Subscribe

Contact us